Insider Transactions in Q4 2025 at Veracyte, Inc. (VCYT)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 10
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,102
-11.64%
|
$214,284
$42.33 P/Share
|
|
Nov 07
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
5,818
-11.71%
|
$232,720
$40.21 P/Share
|
|
Nov 05
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,000
-5.26%
|
$287,000
$41.0 P/Share
|
|
Nov 05
2025
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
9,674
-41.65%
|
$386,960
$40.02 P/Share
|
|
Nov 05
2025
|
Evan/ Fa Jones Director |
SELL
Open market or private sale
|
Direct |
43,196
-12.11%
|
$1,900,624
$44.29 P/Share
|
|
Nov 05
2025
|
Evan/ Fa Jones Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+13.75%
|
$180,000
$6.94 P/Share
|
|
Nov 05
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
6,466
-7.23%
|
$258,640
$40.0 P/Share
|
|
Oct 28
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,886
+5.49%
|
-
|
|
Oct 06
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
8,349
-8.28%
|
$300,564
$36.02 P/Share
|
|
Oct 01
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,160
-2.36%
|
$75,600
$35.0 P/Share
|
|
Oct 01
2025
|
Robert S Epstein Director |
SELL
Open market or private sale
|
Direct |
21,473
-25.59%
|
$751,555
$35.08 P/Share
|
|
Oct 01
2025
|
Robert S Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+10.65%
|
$70,000
$7.94 P/Share
|
|
Oct 01
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
2,539
-2.77%
|
$88,865
$35.0 P/Share
|